Initiation of TACTI-004 phase 3 trial in 1st line NSCLC
Filed with ASX · · 2 pages · English
Story so far
Earlier from Immutep
- Excellent Survival Data from INSIGHT-003 Trial in NSCLC
- Positive Data from Phase II Trial in Soft Tissue Sarcoma
- Enrolment for Ph II AIPAC-003 Breast Cancer Trial Completed
- Immutep receives A$3.6 million French R&D Tax Incentive
- New Positive Efficacy Data for Efti in Head and Neck Cancer
Later from Immutep
- Immutep Reports Promising New Data in Head and Neck Cancer
- Immutep announces initial safety data from IMP761 phase 1
- Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025
- First patient dosed in phase 3 TACTI-004 lung cancer trial
- First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep